#Biotechnology is the focus of #DBT2022 in Hamburg. It‘s all about #Innovation, #Technology and #Enablement

#DBT2022 It‘s a long way for #biotech #Startups to actually make it from a great idea to the last phase, the #Commercialization. Without an ecosystem supporting partnerships and capitalization #innovation isn‘t possible. @glpg_DE #VentureCapital #lifesciences

#DBT2022 #Innovationen im Bereich #Biotechnologie in Deutschland: wir brauchen gezielte Agenda, die #Investitionsanreize schafft. Rahmenbedingungen für private #Investoren müssen verbessert werden. #VentureCapital #lifescience @BIODeutschland

We are very disappointed that #EU changed its position on Waiving IP for COVID technologies. States should be concerned. What should investors expect in the future if IP is not respected? Read what this means for future #innovations in the medical sector. bit.ly/3ai0Eqi

Listen to @westermann_r , Chairman of Life Sciences Acceleration Alliance , gold sponsor of HTID#4. After the launch of LSAA during HTID#3, LSAA is back, just discover why! Meet LSAA during HTID#4 on October 13&14 2022! More information: htfc-eu.com/htid/

LSAA is very pleased to attend the #HTID again this year. Starting off the day with this powerful quote from Pierre Courteille: “Europe needs dynamic, resilient ecosystems, provider of innovative solutions and growth financing”. Stay tuned for more live updates! #LSAA #HTID4

Heard at #HTID4: "Translating Scientific Discoveries into Health Technologies: #IPprotection is critical in this complex journey." - Michel Goldman, President I3h Institute at the Free University of Brussels.

LSAA was part of the panel on “Covid wake up call on health innovation investments: opportunities and turbulence” along other key actors in the industry. Thank you to Cédric Moreau for moderating the conversation. #LSAA #HTID4

"Although the Ukrainian & Russian conflict is impacting investment and resources, VCs are still continuing to support biotech. Pharma companies are looking for innovation & we are seeing an increase in M&A activity with American investors coming to Europe" Elena Coluccelli #HTID4

"The EU commission is planning to review its current regulations, after more than 20 years. This could either go wrong or go right. But let's say that this is a great opportunity for Europe to rethink its framework & rebuild its independence, attractiveness & leadership." - LSAA

"The pandemic and the past two years should be a wake up call for all of us. We need investors and #VCs to stand together to limit #TRIPSwaiver impact on the longterm." Yann Le Flohic, Deputy Chairman of #LSAA at #HTID4

#HTID4: here we go for a second day of conferences and conversations with key actors of the #LifeScience investment community! #LSAA

#TBT to #HTID4 & the amazing time we had with the new edition’s participants/panelists (VCs, Investors...) from all over the world. It's always great to connect/meet with those who are making a difference. Special shoutout to Cedric Moreau from Sofinnova Partners & #HTID2022 organizers

Investment in medicines impacted by the U.S' Inflation Reduction Act will plummet. In the growing EU life science market, imagine what similar price setting measures could mean for the future development of life saving drugs. Watch our full webinar here bit.ly/3EQvraZ

At #HTID4 Hubert Gambs, Deputy Director-General DG Grow, was asked about the big initiatives coming up at an EU-level - including the revision of the pharmaceutical legislation. Watch his take on the subject here. #investors #IPrights #VCs

What should the European Commission consider as it undertakes its review of #pharmaceutical legislation? Incubate Coalition Executive Director John Stanford thinks two of the most important considerations are not only economic costs, but patient costs. bit.ly/3gn5Egt

In the wake of the drug pricing policies set by the Inflation Reduction Act, European policy makers may have an opportunity to build an inviting environment for the early-stage life science ecosystem. Watch our full webinar here: bit.ly/3DuHutr #InflationReductionAct

Check out Christian Pierret's thoughts on European funding for #innovation, the duration of patent protection, and other hot life sciences topics in his Les Echos opinion out last week. #lifesciences #patentprotection bit.ly/3LpvrSK

In case you missed it, take a look at Christian Pierret's Les Echos piece on the European Commission's upcoming pharmaceutical proposal.